Hematologic Malignancies

Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN

Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN

By

A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.

Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample

Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample

By

MIT team develops simple, less painful diagnostic test for multiple myeloma using microfluidic chip and conventional blood sample.

Optimal Management of Myeloma With Bortezomib

Optimal Management of Myeloma With Bortezomib

By

In this review of the role of bortezomib in the treatment of multiple myeloma, the researchers explain what nurses need to watch for in patients taking this drug.

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.

New Gene Mutations Associated with Erdheim-Chester Disease Could Improve Treatment Options

New Gene Mutations Associated with Erdheim-Chester Disease Could Improve Treatment Options

By

BRAF other MAPK pathway gene mutations associated with Erdheim-Chester disease reveal that ECD is a neoplastic disease.

Psoriasis May Increase Risk of Melanoma and Hematologic Cancers

Psoriasis May Increase Risk of Melanoma and Hematologic Cancers

Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.

Letermovir Reduces CMV Infection, Improves Survival After Stem Cell Transplantation

Letermovir Reduces CMV Infection, Improves Survival After Stem Cell Transplantation

By

A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.

Hematologic Oral Chemotherapy Clinic Reduces Emergency Department Visits

Hematologic Oral Chemotherapy Clinic Reduces Emergency Department Visits

By

A hematologic multidisciplinary oral chemotherapy clinic established at a community hospital identified adverse events early and reduced ED visits.

Carfilzomib Improves OS vs Bortezomib in R/R Multiple Myeloma

Carfilzomib Improves OS vs Bortezomib in R/R Multiple Myeloma

By

Carfilzomib significantly prolonged overall survival compared with bortezomib in patients with relapsed or refractory multiple myeloma.

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

By

Younger and usual adult body mass index (BMI) may be linked to increased risk for developing multiple myeloma, research indicates.

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

By

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

By

Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

By

Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

By

PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.

BBD Regimen Efficacious as First-line Therapy for Myeloma

BBD Regimen Efficacious as First-line Therapy for Myeloma

By

Bendamustine, bortezomib, and dexamethasone is efficacious and tolerable as first-line therapy for patients with myeloma ineligible to receive high-dose therapy.

Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers

Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers

By

Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

By

Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.

Anxiety, Distress Common Among Patients With BCR-ABL-negative MPNs

Anxiety, Distress Common Among Patients With BCR-ABL-negative MPNs

By

In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

By

Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

By

Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.

Data Confirm Auto-HCT as Standard Approach for Myeloma in Young Patients

Data Confirm Auto-HCT as Standard Approach for Myeloma in Young Patients

By

A pooled analysis confirms the role of upfront autologous HCT as the standard approach for all young patients with multiple myeloma.

What Is The Optimal Sequencing of Novel Agents for CLL?

What Is The Optimal Sequencing of Novel Agents for CLL?

By

Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.

VT Maintenance Improves PFS vs Thalidomide or Interferon in Myeloma

VT Maintenance Improves PFS vs Thalidomide or Interferon in Myeloma

By

In this study, maintenance therapy with bortezomib plus thalidomide was compared with thalidomide alone or interferon alfa-2b alone in patients with newly diagnosed symptomatic multiple myeloma. Study findings demonstrate an impact on progression-free survival.

Pretransplant Depression Associated With Worse Overall Survival

Pretransplant Depression Associated With Worse Overall Survival

By

An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.

Nilotinib for CML Associated With Improved Quality of Life

Nilotinib for CML Associated With Improved Quality of Life

By

Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.

Adding Pioglitazone to Imatinib May Improve Response in CML

Adding Pioglitazone to Imatinib May Improve Response in CML

By

Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

By

Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.

Racial Disparities Persist in Myeloma Treatment Use

Racial Disparities Persist in Myeloma Treatment Use

By

Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.

Ruxolitinib May Improve Symptom Control in Patients With CLL

Ruxolitinib May Improve Symptom Control in Patients With CLL

By

In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs